Early use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact

about

Early use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact

Item

http://www.wikidata.org/entity/Q58799763

description

im Juni 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 07 June 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Early use of the HPV 2-dose va ...... policy for accelerated impact

@en

Early use of the HPV 2-dose va ...... policy for accelerated impact

@nl

type

Item

label

Early use of the HPV 2-dose va ...... policy for accelerated impact

@en

Early use of the HPV 2-dose va ...... policy for accelerated impact

@nl

prefLabel

Early use of the HPV 2-dose va ...... policy for accelerated impact

@en

Early use of the HPV 2-dose va ...... policy for accelerated impact

@nl

P1476

Early use of the HPV 2-dose va ...... policy for accelerated impact

@en

P2093

Chantal Sauvageau

http://www.w3.org/2001/XMLSchema#string

Eduardo Lazcano-Ponce

http://www.w3.org/2001/XMLSchema#string

Gina Ogilvie

http://www.w3.org/2001/XMLSchema#string

Monica Naus

http://www.w3.org/2001/XMLSchema#string

Monique Landry

http://www.w3.org/2001/XMLSchema#string

Vladimir Gilca

http://www.w3.org/2001/XMLSchema#string

P2860

Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience

Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial

Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.

Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.

Efficacy of Human Papillomavirus L1 Protein Vaccines (Cervarix and Gardasil) in Reducing the Risk of Cervical Intraepithelial Neoplasia: A Meta-analysis.

Implementation of a human papillomavirus vaccination demonstration project in Malawi: successes and challenges

Vaccination to prevent human papillomavirus infections: From promise to practice.

Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.

P304

4800-4805

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2018.02.004

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

32 Pt A

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jorge Salmerón

P577

2018-06-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29887322

http://www.w3.org/2001/XMLSchema#string

P921

infectious disease

molecular medicine

P932

6078939

http://www.w3.org/2001/XMLSchema#string